Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04837209 · ClinicalTrials.gov registry record · Phase 2
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
A Phase 2 study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 4
- Study locations
NCT04837209 is a Phase 2 study of Breast Cancer and Triple Negative Breast Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 32 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04837209, a Phase 2 study of Breast Cancer and Triple Negative Breast Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer. The names of the study treatment involved in this study are: * Dostarlimab * Niraparib * Radiation Therapy (RT), which is given per standard of care.
Conditions Studied
Interventions
- RADIATION Radiation therapy
- DRUG Niraparib
- DRUG Dostarlimab
Study Locations (4)
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
North Carolina
- Duke University Medical Center - Durham
Pennsylvania
- University of Pennsylvania Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-07-21 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04837209
The ClinicalTrials.gov registry entry for NCT04837209 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Radiation therapy is the first listed.
NCT04837209 reports 4 study locations spanning 4 distinct geographic areas - top geographies include District of Columbia, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04837209 about?
NCT04837209 is a clinical study titled "Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer". This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer. The names of the study treatment involved in this study are: * Dostarlimab * Niraparib * Radia...
What is the current status of trial NCT04837209?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2021-07-21. Estimated completion is 2029-12-01.
What conditions does trial NCT04837209 study?
This clinical trial studies the following conditions: Breast Cancer, Triple Negative Breast Cancer.
What interventions are being tested in trial NCT04837209?
The interventions under investigation include: Radiation therapy (RADIATION), Niraparib (DRUG), Dostarlimab (DRUG).
Who is sponsoring clinical trial NCT04837209?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04837209 being conducted?
This trial has 4 study locations across District of Columbia, Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Breast Cancer
All registered trials for this condition
Triple Negative Breast Cancer
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.